Clinical trials: PSMA PET/CT
Prostate Cancer, PSMA PET/CT
Brief Title: INTROSPECT: Intraoperative PSMA PET/CT Imaging During Radical Prostatectomy
During prostate cancer surgery, the surgeon aims to remove the tumor completely while preserving the surrounding tissue responsible for urinary continence and sexual potency.
- Conditions
- Prostate Cancer, PSMA PET/CT, Margin Assessment
- Trial name
- INTROSPECT (NCT07829068)
- Testing
- study-specific administration of 68Ga-PSMA-11 followed by ex vivo PET/CT imaging of the prostatectomy specimen
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Geneva
Prostatic Neoplasms, Prostatectomy
a Study of Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients Performing Radical Prostatectomy Without Biopsy
This is an observational, open, single-arm, prospective, staged entry（based on Fleming's Group-Sequential Design） clinical study The Goal is to evaluate the feasibility and clinical value of direct robot assisted laparoscopic…
- Conditions
- Prostatic Neoplasms, Prostatectomy, Prostate Biopsy
- Trial name
- NCT05670691
- Volunteers
- 71 people
- Sponsor
- Fudan University
Tumour of Epithelial Origin, 68Ga-MY6349
A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours
This is a study using an autocontrol approach, enrolling 40 patients with tumours of epithelial origin, who underwent 68Ga- MY6349 and 68Ga-PSMA/18F-FDG PET/CT imaging of patients with tumours of epithelial origin to compare the…
- Trial name
- NCT06770478
- Testing
- 68Ga-MY6349 PET/CT Scan
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xijing Hospital
Prostate Cancer
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer
This is a prospective, open-label, multicenter, Phase I/II exploratory diagnostic imaging study to evaluate the safety, tolerability, radiation dosimetry, pharmacokinetics, biodistribution, imaging characteristics, and…
- Trial name
- COPRA424 (NCT07765940)
- Testing
- [⁶⁴Cu]Cu-RAX301 Injection
- Volunteers
- 52 people
- Sponsor
- RadAlliance Therapeutics, Inc
Prostate Cancer
AI-based Measurements of Tumour Burden in PSMA PET-CT
The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic…
- Trial name
- NCT06363435
- Testing
- AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans
- Where
- 2 sites in Sweden
- Volunteers
- 1,500 people
- Sponsor
- Elin Tragardh
PSMA Positive Tumors or Tumor Tissues, Prostate Cancer Metastatic
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies.
- Trial name
- PELICAN (NCT07089550)
- Testing
- PSMA PET/CT scan
- Where
- 4 sites in Italy
- Volunteers
- 1,300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
This multicenter retrospective study developed and validated a prediction model based on PSMA PET/CT and routine clinical information to estimate early treatment response in patients with metastatic hormone-sensitive prostate…
- Trial name
- NCT07428642
- Testing
- Androgen Deprivation Therapy, Apalutamide, Enzalutamide
- Where
- China
- Volunteers
- 168 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Prostate Cancer
[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients
To investigate the radioactive uptake of [Al 18 F]PSMA137 in PCa patients, and evaluate the ability of [Al 18 F]PSMA137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).To provide an…
- Trial name
- NCT04693169
- Testing
- 11C-Choline
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Prostate Cancer Metastatic, Prostate Cancer
Dutch National Randomized Study: PSMA-PET/CT As a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients
To determine if the use of Prostate-Specific Membrane Antigen Positron Emission Computer Tomography (PSMA PET/CT) as a selection tool for performing extended lymph node dissection (ePLND) for prostate cancer (PCa) in the primary…
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer, Lymph Node Metastases
- Trial name
- PSMA-SELECT (NCT05000827)
- Testing
- PSMA-PET/CT, Nomogram
- Where
- Netherlands
- Volunteers
- 706 people
- Sponsor
- Canisius-Wilhelmina Hospital
Metastatic Castration-resistant Prostate Cancer
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04631601
- Testing
- Acapatamab, Enzalutamide, Abiraterone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 55 people
- Sponsor
- Amgen
Prostate Cancer, Prostate Adenocarcinoma
Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy
The study is a non-randomized, prospective trial of men scheduled for radical prostatectomy for treatment of prostate cancer as standard of care and will undergo a series of pre-operative multi-modality imaging studies.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
- Trial name
- IGPC-5 (NCT04053842)
- Testing
- PET Scan, [18F]PSMA-1007 Injection, Sodium MRI
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Glenn Bauman
RCC, Renal Cell Cancer
A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET/CT Imaging
This is a prospective, open-label, single-center clinical study targeting renal cell carcinoma. Sixty patients with a high clinical suspicion of renal cell carcinoma were included.
- Trial name
- NCT06769893
- Testing
- 68Ga-NOTA-RCCB6 PET/CT Scan
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
The purpose of this study was to evaluate the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT).
- Trial name
- GuideView (NCT04838626)
- Testing
- [18F]CTT1057
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 195 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
68Ga-NTA-476 Imaging in Prostate Cancer
This study is investigating a new agent to be used in PET imaging for prostate cancer, called 68Ga-NTA-476. It aims to find out where 68Ga-NTA-476 goes in the body once it is injected into a person and whether there are any side…
- Trial name
- NTA-476 (NCT06520449)
- Testing
- 68Ga-NTA-476
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Melbourne Theranostic Innovation Centre
Prostate Cancer, Cancer Recurrence
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years. The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT).
- Trial name
- PERYTON (NCT04642027)
- Testing
- Conventional sEBRT, Hypofractionated sEBRT
- Where
- 13 sites in Netherlands
- Volunteers
- 538 people
- Sponsor
- University Medical Center Groningen
Prostate Cancer
Integrated 18F-labelled PSMA Project
There are several new therapies available to treat men with advanced prostate cancer; however, the decision making tools needed to determine the best treatment for these patients are noticeably absent.
- Trial name
- NCT02691169
- Testing
- 18F-DCFPyL
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Glioma, Malignant, Glioma Glioblastoma Multiforme
Predictive Values of Preoperative [68Ga]Ga-PSMA-11 PET/CT in Patients With Suspected Brain Tumours of Glial Origin
The aim of this study was to analyse usefulness of [68Ga]Ga-PSMA-11 PET/CT scans in preoperative differentiation between HGG and LGG in patients with suspicion of a tumor of glial origin in previously performed imaging…
- Trial name
- NCT05896449
- Testing
- [68Ga]Ga-PSMA-11 PET/CT
- Where
- Poland
- Volunteers
- 49 people
- Sponsor
- Medical University of Warsaw
Metastatic Prostate Cancer
177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study
This is a Phase 1 trial of TLX591, a monoclonal antibody HuX591 conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591).
- Trial name
- ProstACTSelect (NCT04786847)
- Testing
- 177Lu-DOTA-TLX591
- Where
- 3 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients
The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen ([Ga-68]PSMA) for detection of bone metastasis in patients with prostate cancer.
- Trial name
- NCT05527483
- Testing
- [68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University Hospitals Cleveland Medical Center
Multiple Myeloma
A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma
Multiple myeloma (MM) is the second most common hematological malignancy and is still incurable. Positron emission tomography/computed tomography (PET/CT) has been used to diagnose, assess treatment response, and predict…
- Trial name
- NCT05448404
- Testing
- 18F-PSMA-1007, 18F-FDG
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Hospital of China Medical University